
An experimental drug may one day be a cure for eczema, a new trial suggests. The drug, rocatinlimab, is a monoclonal antibody that researchers found prevented the recurrence of the symptoms of the skin condition for up to 20 weeks after treatment was stopped. “Patients ask us in the clinic all the time, ‘Can I stop the medication, or can I start doing it much less often?’ Right now we don’t have those medications available,” said lead researcher Dr. Emma Guttman, professor and system chair of dermatology and immunology at the Icahn School of Medicine at Mount Sinai in New York City. “Of course, it’s important in adults, but imagine, in the future, how important this is in children. This drug may cause disease modification because it works on memory T-cells,” she explained. The drug works by blocking OX40 — an immune molecule that activates inflammatory cells that play a role in the development of eczema, also called atopic dermatitis. The drug also prevents memory T-cells from storing the key to eczema. “Because it works on memory T-cell formation, the cells that remember that the patient has the disease, maybe these cells will not come back to cause the disease again,” Guttman said. Atopic dermatitis is a debilitating chronic inflammatory skin disease, which often develops at a very young age, causing the skin to become… read on > read on >